Shuttle Pharmaceuticals Holdings, Inc.
For the period ended Sep 9, 2026. Filed Sep 16, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Sep 9, 2026 · Filed Sep 16, 2026
Use the contents to explore the available documents and sections.
Contents
PROXY STATEMENT
Proxy Statement on Schedule 14A filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) on August 13, 2026, as supplemented (the “Proxy Statement”). The voting results of the Meeting were reported on a Current Report on Form 8-K filed with the SEC on September 11, 2026.
As of September 14, 2026, the Company issued an aggregate of (a) 2,869,595 shares of the Company’s common stock, par value $0.00001 per share (“Common Stock”), upon the conversion of certain of its issued and outstanding shares of Series B-1 Preferred Stock (the “B-1 Preferred Stock”) and (b) 867,887 shares of Common Stock upon the conversion of certain of its issued and outstanding shares of Series B-2 Preferred Stock (the “B-2 Preferred Stock” and with the B-1 Preferred Stock, the “Preferred Stock”). The issuance of such shares of Common Stock takes into account the 4.99%
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.